These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18808313)

  • 1. ASA404: update on drug development.
    Rehman F; Rustin G
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1547-51. PubMed ID: 18808313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
    Head M; Jameson MB
    Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
    Baguley BC; Siemann DW
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1413-25. PubMed ID: 20964495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular toxicity profiles of vascular-disrupting agents.
    Subbiah IM; Lenihan DJ; Tsimberidou AM
    Oncologist; 2011; 16(8):1120-30. PubMed ID: 21742963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
    McKeage MJ; Baguley BC
    Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.
    Baguley BC; McKeage MJ
    Future Oncol; 2010 Oct; 6(10):1537-43. PubMed ID: 21062153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
    Lorusso PM; Boerner SA; Hunsberger S
    J Clin Oncol; 2011 Aug; 29(22):2952-5. PubMed ID: 21709201
    [No Abstract]   [Full Text] [Related]  

  • 11. An overview on Vadimezan (DMXAA): The vascular disrupting agent.
    Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Samandari-Rad S; Zarghami N
    Chem Biol Drug Des; 2018 May; 91(5):996-1006. PubMed ID: 29288534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular disrupting agents (VDAs) in anticancer therapy.
    Daenen LG; Roodhart JM; Shaked Y; Voest EE
    Curr Clin Pharmacol; 2010 Aug; 5(3):178-85. PubMed ID: 20406172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
    Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular-disrupting agents in oncology.
    Mita MM; Sargsyan L; Mita AC; Spear M
    Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents target existing tumor vasculature.
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
    [No Abstract]   [Full Text] [Related]  

  • 16. Vascular disrupting agents: a new class of drug in cancer therapy.
    Gaya AM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.
    Jameson MB; Sharp DM; Sissingh JI; Hogg CR; Thompson PI; McKeage MJ; Jeffery M; Waller S; Acton G; Green C; Baguley BC
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2553-9. PubMed ID: 19387077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
    McPhail LD; Griffiths JR; Robinson SP
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.
    McKeage MJ
    Clin Lung Cancer; 2011 May; 12(3):143-7. PubMed ID: 21663855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular disrupting agents in clinical development.
    Hinnen P; Eskens FA
    Br J Cancer; 2007 Apr; 96(8):1159-65. PubMed ID: 17375046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.